China’s biotech sector is making global headlines as a new wave of licensing deals reshapes how innovative drug candidates reach international markets. At the center of this trend is the NewCo licensing model, which has rapidly gained traction and positioned Chinese biotechs as key beneficiaries of cross-border pharmaceutical collaboration.
Unlike traditional licensing agreements, where rights are transferred directly to a major pharmaceutical company, the NewCo model creates a newly formed entity, often backed by global venture investors, outside of China. The original biotech developer then retains equity in this NewCo, allowing it to share in future international revenues while avoiding the heavy costs of late-stage clinical trials and global marketing.
Recent deals showcase the momentum. Mabwell Bioscience signed a landmark agreement with Aditum Bio’s NewCo Kalexo Bio, granting global rights to its siRNA candidate 2-MW7141 in a deal valued at up to $1 billion. Mabwell now holds equity in Kalexo, ensuring continued participation in the drug’s international success. Similarly, Jiangsu Hengrui Pharmaceuticals has embraced the model, granting ex-China rights for its cardiomyopathy drug HRS-1893 to NewCo Braveheart Bio for $1.1 billion.
These partnerships highlight the growing global confidence in Chinese innovation. As more international investors commit capital to NewCos, Chinese biotechs benefit from upfront payments, royalties, and long-term equity value, all while focusing their domestic resources on innovation and early-stage development.
Industry leaders note that NewCo deals thrive when candidates show clear global differentiation and strong clinical potential. This reflects the strength of China’s biotech pipelines, which now span advanced modalities such as RNA therapies, bispecific antibodies, and cell-based treatments. Akeso Biopharma’s $5 billion outlicensing deal for its bispecific antibody ivonescimab stands as another example of the country’s ability to bring novel therapies into global markets, where it is now advancing in several Phase III studies.
Behind this success lies decades of investment in biomedical infrastructure, clinical networks, and regulatory reform. National strategies such as “Made in China 2025” and “Healthy China 2030” have accelerated breakthroughs in novel therapies, while the country’s robust hospital system and broad patient base have enabled efficient, high-quality early-stage trials. These foundations are now paying dividends, with Chinese companies increasingly seen as reliable partners for global drug development.
Global pharma has taken notice. Companies worldwide are tapping China’s rich pool of preclinical and clinical assets to strengthen their pipelines, while venture capital firms are fueling new partnerships through the NewCo structure. The result is a win-win: Chinese biotechs extend their global reach and share in international sales, while patients around the world gain access to promising new therapies born out of China’s innovation ecosystem.
China’s growing role in global biopharma is not just a sign of sector maturity, it is a positive signal of the country’s ability to drive healthcare innovation worldwide. The rise of the NewCo model demonstrates that China is no longer just a participant in the global biotech landscape, but a central hub for groundbreaking ideas, transformative therapies, and international collaboration.